ArticleERJ open research2026
microRNAs as epigenetic biomarkers for CTEPH: a case-control study towards personalised medicine.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe complication of acute pulmonary embolism (PE) in which delayed diagnosis significantly affects patient health outcomes. This case-control study aimed to identify a set of microRNAs (miRNAs) in plasma with diagnostic potential to differentiate patients with CTEPH from those with PE. Methods: Two groups were analysed: 22 patients with confirmed CTEPH and 13 patients with PE, followed by validation in an independent cohort of 48 CTEPH and 37 PE patients. Results: Using real-time PCR, eight miRNAs were identified as significantly different between the groups: miR-574-3p, miR-146b-5p, miR-193a-5p, miR-885-5p, miR-122-5p, miR-365a-3p, miR-142-3p and miR-192-5p. These miRNAs target key biological pathways, including vascular smooth muscle contraction, apoptosis and VEGF signalling, underlying the pathophysiology of CTEPH. The miRNA panel demonstrated strong diagnostic accuracy with an area under the curve of 0.843 in the validation cohort. Conclusions: The results highlight the potential of miRNA biomarkers as a diagnostic tool for early detection of CTEPH, representing a paradigm shift in its management, but further validation in larger cohorts is necessary to confirm their applicability. These insights could pave the way for improved clinical outcomes through timely diagnosis and targeted interventions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.